Epizyme, Inc. (EPZM) Stock Price Up -5.2%
Epizyme, Inc. (NASDAQ:EPZM)’s share price rose 5.2% during mid-day trading on Tuesday . The company traded as high as $20.45 and last traded at $19.05. Approximately 348,094 shares changed hands during trading, a decline of 40% from the average daily volume of 581,814 shares. The stock had previously closed at $20.10.
EPZM has been the subject of a number of recent research reports. BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Oppenheimer Holdings, Inc. set a $26.00 target price on Epizyme and gave the company a “buy” rating in a report on Monday, June 5th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Epizyme in a report on Wednesday, June 7th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $20.00 target price on shares of Epizyme in a research report on Friday, September 15th. Finally, ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $23.33.
The firm’s market capitalization is $1.13 billion. The stock’s 50-day moving average is $16.79 and its 200-day moving average is $15.37.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.08. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. The company’s quarterly revenue was up 2027.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.49) EPS. On average, equities research analysts anticipate that Epizyme, Inc. will post ($2.36) EPS for the current year.
In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total transaction of $235,200.00. Following the sale, the insider now directly owns 22,228 shares in the company, valued at approximately $348,535.04. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David M. Mott bought 200,000 shares of the business’s stock in a transaction on Monday, September 18th. The shares were acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at approximately $91,500. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 45,000 shares of company stock valued at $688,950. 25.20% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of EPZM. Lord Abbett & CO. LLC bought a new position in Epizyme during the 2nd quarter valued at about $9,726,000. The Manufacturers Life Insurance Company grew its stake in shares of Epizyme by 3.3% in the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after acquiring an additional 1,068 shares during the period. State Street Corp grew its stake in shares of Epizyme by 59.6% in the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after acquiring an additional 658,727 shares during the period. Palo Alto Investors LLC grew its stake in shares of Epizyme by 18.9% in the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock worth $86,044,000 after acquiring an additional 907,245 shares during the period. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Epizyme in the second quarter worth approximately $215,000. Hedge funds and other institutional investors own 72.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/03/epizyme-inc-epzm-stock-price-up-5-2.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.